American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 895-901.e1 , December 2009

Aqueous Vascular Endothelial Growth Factor as a Predictor of Macular Thickening Following Cataract Surgery in Patients With Diabetes Mellitus

  • M. Elizabeth Hartnett

      Affiliations

    • Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
    • Corresponding Author InformationInquiries to M. Elizabeth Hartnett, Dept of Ophthalmology, University of North Carolina, 5100 Bioinformatics Building, CB #7040, Chapel Hill, NC 27599
    • ,
  • Nicholas Tinkham

      Affiliations

    • Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Lauren Paynter

      Affiliations

    • Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Pete Geisen

      Affiliations

    • Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Pinchas Rosenberg

      Affiliations

    • Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Gary Koch

      Affiliations

    • Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina
    • ,
  • Kenneth L. Cohen

      Affiliations

    • Department of Ophthalmology, University of North Carolina, Chapel Hill, North Carolina

,Accepted 15 July 2009.

References 

  1. Jaffe GJ, Burton TC, Kuhn E, Prescott A, Hartz A. Progression of nonproliferative diabetic retinopathy and visual outcome after extracapsular cataract extraction and intraocular lens implantation. Am J Ophthalmol. 1992;114:448–456
  2. Henderson BA, Kim JY, Ament CS, Ferrufino-Ponce ZK, Grabowska A, Cremers SL. Clinical pseudophakic cystoid macular edema: Risk factors for development and duration after treatment. J Cataract Refract Surg. 2007;33:1550–1558
  3. Chew EY, Benson WE, Remaley NA, et al. Results after lens extraction in patients with diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report No. 25. Arch Ophthalmol. 1999;117:1600–1606
  4. Suto C, Hori S, Kato S, Muraoka K, Kitano S. Effect of perioperative glycemic control in progression of diabetic retinopathy and maculopathy. Arch Ophthalmol. 2006;124:38–45
  5. Benson WE, Brown GC, Tasman W, McNamara JA, Vander JF. Extracapsular cataract extraction with placement of a posterior chamber lens in patients with diabetic retinopathy. Ophthalmology. 1993;100:730–738
  6. Escaravage GK, Cohen KL, Patel SB, Hartnett ME, Armstrong BD, Janowski CM. Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. J Cataract Refract Surg. 2006;32:803–811
  7. Kim SJ, Equi R, Bressler NM. Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology. 2007;114:881–889
  8. Cardillo JA, Melo LA, Costa RA, et al. Comparison of intravitreal versus posterior sub-Tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557–1563
  9. Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005;139:802–806
  10. Aiello LP, Bursell S, Clermont A, et al. Vascular endothelial growth factor induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473–1480
  11. Campochiaro PA. Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today (Barc). 2007;43:529–537
  12. Diabetic Retinopathy Clinical Research Network. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860–1867
  13. Arevalo JF, Garcia-Amaris RA, Roca JA, et al. Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: Pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg. 2007;33:2098–2105
  14. Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg. 2008;34:70–75
  15. Funatsu H, Yamashita H, Noma H, Shimizu E, Mimura T, Hori S. Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy. J Cataract Refract Surg. 2002;28:1355–1363
  16. Roh MI, Kim HS, Song JH, Lim JB, Kwon OW. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology. 2009;116:80–86
  17. Wedrychowicz A, Dziatkowiak H, Nazim J, Sztefko K. Insulin-like growth factor-1 and its binding proteins, IGFBP-1 and IGFBP-3, in adolescents with type-1 diabetes mellitus and microalbuminuria. Horm Res. 2005;63:245–251
  18. Uthra S, Raman R, Mukesh BN, et al. Diabetic retinopathy and IGF-1 gene polymorphic cytosine-adenine repeats in a Southern Indian cohort. Ophthalmic Res. 2007;39:294–299
  19. Chantelau E, Frystyk J. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration—a case report. Growth Horm IGF Res. 2005;15:130–135
  20. Ruberte J, Ayuso E, Navarro M, et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest. 2004;113:1149–1157
  21. Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997;276:1706–1709
  22. Smith LEH, Shen W, Peruzzu C, et al. Regulation of vascular endothelial growth factor–dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med. 1999;5:1390–1395
  23. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–1682
  24. Early Treatment Diabetic Retinopathy Study. Photocoagulation for diabetic macular edema (Early Treatment Diabetic Retinopathy Study Report No. 1). Arch Ophthalmol. 1985;103:1796–1806
  25. Diabetic Retinopathy Clinical Research Network. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007;114:1520–1525
  26. Lobo CL, Faria PM, Soares MA, Bernardes RC, Cunha-Vaz JG. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30:752–760
  27. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70–77
  28. Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium–derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2006;113:294–301
  29. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690–1696
  30. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354–1360
  31. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res. 2000;6:3147–3152
  32. Kim SJ, Choi IK, Park KH, et al. Serum Vascular endothelial growth factor per platelet count in hepatocellular carcinoma: correlations with clinical parameters and survival. Jpn J Clin Oncol. 2004;34:184–190
  33. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen?. Int J Oncol. 2000;17:149–152
  34. Wynendaele W, Derua R, Hoylaerts MF, et al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?. Ann Oncol. 1999;10:965–971
  35. Cavusoglu AC, Bilgili S, Alaluf A, et al. Vascular endothelial growth factor level in the serum of diabetic patients with retinopathy. Ann Ophthalmol (Skokie). 2007;39:205–208
  36. Sydorova M, Lee MS. Vascular endothelial growth factor levels in vitreous and serum of patients with either proliferative diabetic retinopathy or proliferative vitreoretinopathy. Ophthalmic Res. 2005;37:188–190

PII: S0002-9394(09)00512-1

doi: 10.1016/j.ajo.2009.07.014

American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 895-901.e1 , December 2009

Article Tools